Masimo vs. Apple: The Ongoing Legal Saga Over Blood Oxygen Sensor Technology
A Six-Year Legal Battle
In the realm of technology and innovation, disputes over intellectual property are prevalent. One such ongoing conflict involves medical technology company Masimo and technology leader Apple. The disagreement pertains to pulse oximetry patents utilized in Apple Watch models. The legal battle commenced in 2020 when Masimo initiated a lawsuit against Apple, alleging the company infringed upon their blood oxygen sensor technology patents.
Legal Victories and Setbacks
Masimo scored a key victory in January 2023 when the International Trade Commission (ITC) determined that Apple had transgressed its patents. This verdict led to an ITC suggestion to prohibit the importation of specific Apple Watch models into the United States. However, Apple’s tactical software update, which deactivated the purportedly infringing feature, enabled them to keep selling the products without contravening the ITC ruling.
Recent Developments
In a mixed development for Masimo, the US Court of Appeal for the Federal Circuit recently affirmed the ITC’s initial ruling. This judgment obligates Apple to incur costs but does not require additional actions to resolve the case. Notably, the ITC also specified that Apple’s redesign had evaded the patent concerns, permitting ongoing sales of the Apple Watch.
Apple’s Response and Future Innovations
Apple has persistently denied Masimo’s allegations, upholding its commitment to innovation and consumer-oriented technology advancement. In spite of the continuing legal hurdles, Apple continues to stress its dedication to creating leading health and wellness features in its offerings.
The $634 Million Verdict
In November 2025, Masimo achieved a $634 million verdict in a federal jury trial, marking a significant financial triumph. Nevertheless, Apple indicated its plan to contest this ruling, asserting that it contradicted the facts.
The Road Ahead
As the legal conflict continues, the expiration of the disputed patents in under three years may offer a resolution. Until that point, both companies remain steadfast in their positions, with Masimo concentrating on safeguarding its innovations and Apple on defending its product lines.
Conclusion
The ongoing legal contention between Masimo and Apple underscores the intricate nature of intellectual property rights within the tech sector. While Masimo has attained some successes, Apple’s strategic actions have permitted it to persist in marketing its popular products uninterruptedly. As the legal proceedings progress, the technology industry observes closely to discern how this narrative will shape future innovation and patent legislation.
Q&A Session
What are the main patents in dispute between Masimo and Apple?
The disagreement primarily centers around technologies associated with pulse oximetry, which are utilized in monitoring blood oxygen levels in Apple Watch models.
How did Apple respond to the ITC’s ruling?
Apple reacted by deploying a software update to disable the infringing feature, thus facilitating the ongoing sale of its products without breaching the ITC’s ban.
What was the outcome of Masimo’s $634 million verdict?
Masimo achieved a considerable financial verdict, but Apple has declared intentions to appeal the ruling.
How might the legal battle between Masimo and Apple end?
The expiration of the relevant patents within the next three years could potentially settle the conflict, allowing Apple to resume utilizing the disputed features without legal consequences.
What impact does this case have on Apple’s product development?
In spite of the legal disputes, Apple remains committed to innovating and providing health and wellness features, which are pivotal to its product development strategy.
How has the ITC’s decision affected Apple’s sales?
Apple’s strategic update enabled it to bypass the ITC’s ban, ensuring that sales of the affected Apple Watch models continue without interruption.
